Tirzepatide
- Status
- FDA Approved
- Evidence
Approved, human phase 3, graded on the Fat Loss Peptides Bench
It is a 39-amino-acid synthetic peptide based on the native GIP sequence with modifications that confer activity at both GIP and GLP-1 receptors.
Reviewed
01Overview
What Tirzepatide is
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. Tirzepatide features a C20 fatty diacid moiety attached via a linker to facilitate albumin binding, resulting in a plasma half-life of approximately 5 days that supports once-weekly subcutaneous dosing.
Read the full overviewShow less
Tirzepatide is FDA-approved under two brand names: Mounjaro (for type 2 diabetes mellitus, approved May 2022) and Zepbound (for chronic weight management, approved November 2023, and for moderate to severe obstructive sleep apnea in adults with obesity, approved 20 December 2024). It is manufactured by Eli Lilly and Company and represents the first-in-class dual GIP/GLP-1 receptor agonist to reach the market.
The SURMOUNT clinical trial program established tirzepatide as the most effective pharmacological weight loss agent to date. In the SURMOUNT-1 trial, participants with obesity or overweight (without diabetes) receiving tirzepatide 15 mg weekly lost a mean 20.9% of body weight at 72 weeks against 3.1% on placebo, a difference of 17.8 percentage points, for everyone randomized (treatment-regimen estimand). Had everyone stayed on treatment (efficacy estimand), the figures were 22.5% and 2.4%. Notably, 36.2% of participants in the 15 mg group achieved 25% or greater total body weight loss, approaching the magnitude historically seen only with bariatric surgery (PMID: 35658024).
The SURMOUNT-2 trial evaluated tirzepatide in adults with type 2 diabetes and obesity, demonstrating mean weight loss of 14.7% with tirzepatide 15 mg versus 3.2% with placebo at 72 weeks, along with significant HbA1c improvement. The SURMOUNT-3 trial studied tirzepatide following an intensive 12-week lifestyle intervention, showing that tirzepatide maintained and extended initial weight loss while placebo recipients regained weight (PMID: 37840095).
A key differentiating feature of tirzepatide compared to pure GLP-1 receptor agonists such as semaglutide is the GIP receptor agonist component. GIP signaling in adipose tissue is proposed to improve lipid metabolism and may protect against the loss of lean body mass that accompanies caloric restriction and weight loss. Preclinical and early clinical data suggest that tirzepatide-treated patients lose a greater proportion of fat mass relative to lean mass compared to GLP-1-only agents, though this finding requires further validation in dedicated body composition studies.
Tirzepatide achieved the highest absolute weight loss of any anti-obesity medication in clinical trials. At the 15 mg dose, mean weight loss was about 24 kg (52 lb) at 72 weeks in SURMOUNT-1, an efficacy-estimand figure from Lilly that assumes everyone stayed on treatment. The gastrointestinal side effect profile is similar to GLP-1 receptor agonists, with nausea being the most common adverse event, generally mild to moderate and diminishing over time with dose titration.
How it works
Dual GLP-1 and GIP Receptor Agonism
Tirzepatide simultaneously activates two incretin receptors: the GLP-1 receptor and the GIP receptor. While the GLP-1 receptor component provides the well-established effects of GLP-1 agonism (glucose-dependent insulin secretion, glucagon suppression, appetite reduction, delayed gastric emptying), the GIP receptor component adds complementary metabolic effects. GIP receptor activation on pancreatic beta cells enhances glucose-stimulated insulin secretion through a cAMP-PKA pathway that is additive with GLP-1R signaling (PMID: 35658024). Tirzepatide has approximately 5-fold selectivity for the GIP receptor over the GLP-1 receptor, making it a GIP-biased dual agonist.
Read the full mechanismShow less
Enhanced Insulin Secretion Through Dual Incretin Signaling
The combination of GLP-1R and GIPR agonism produces greater insulin secretory response than either pathway alone. In pancreatic beta cells, GLP-1 and GIP activate distinct but converging intracellular signaling cascades — both increase cAMP but through different receptor-G-protein coupling kinetics. This dual stimulation enhances first-phase and second-phase insulin secretion, improving postprandial glucose control. Tirzepatide also suppresses glucagon secretion from alpha cells, contributing to lower fasting and postprandial glucose levels. In SURPASS trials for type 2 diabetes, tirzepatide 15 mg reduced HbA1c by up to 2.58% from a baseline of approximately 8.3%.
Adipose Tissue Lipid Metabolism via GIP Receptor
GIP receptors are expressed on white adipocytes, and their activation promotes lipid uptake, lipogenesis, and adipose tissue remodeling. While this may seem counterintuitive for a weight loss drug, the current hypothesis is that GIP receptor agonism in the context of an energy deficit promotes healthier adipose tissue function — improving lipid storage in subcutaneous depots (metabolically favorable) rather than visceral or ectopic fat depots. This mechanism may explain the observation that tirzepatide produces favorable body composition changes, with proportionally greater fat mass loss relative to lean mass loss compared to GLP-1-only agents (PMID: 35658024).
Central Appetite Suppression
Like semaglutide, tirzepatide acts on hypothalamic and brainstem GLP-1 receptors to reduce appetite. Additionally, GIP receptors are expressed in the central nervous system, including the hypothalamus. Preclinical evidence suggests that central GIPR agonism modulates food intake through pathways partially distinct from GLP-1R signaling, potentially contributing to the greater weight loss observed with dual agonism. Participants in SURMOUNT-1 reported significant reductions in hunger, food cravings, and portion sizes (PMID: 35658024).
Gastric Emptying Delay
Tirzepatide slows gastric emptying, contributing to post-meal satiety and reduced caloric intake. However, the degree of gastric emptying delay with tirzepatide may be slightly less than with pure GLP-1 agonists at equivalent weight loss levels, potentially contributing to slightly better gastrointestinal tolerability in some patients.
Studied for
- Obesity
- Type 2 diabetes
- NASH
- Sleep apnea
- Heart failure with preserved EF
Benefits listed
- Mean body weight reduction of 20.9% at 72 weeks on 15 mg for everyone randomized (treatment-regimen estimand), 22.5% in the efficacy estimand (SURMOUNT-1, PMID: 35658024)
- 36.2% of participants achieved greater than or equal to 25% body weight loss (PMID: 35658024)
- Significant HbA1c reduction in type 2 diabetes (up to 2.4% at 40 weeks in the SURPASS-5 add-on-to-insulin trial) (PMID: 35133415)
- Potentially superior lean mass preservation versus GLP-1-only agents due to GIP component
Show 3 moreShow less
- Dual incretin mechanism providing complementary metabolic benefits
- Improved lipid profiles including triglycerides, LDL cholesterol, and HDL cholesterol
- Reduction in waist circumference and markers of visceral adiposity (PMID: 37840095)
02Research
Free with emailWhat the research shows
Graded on a research bench
Reference pages that put Tirzepatide next to the compounds people pair it with: roles, evidence, overlap and conflicts. No dosing. Research use only.
Unlock the research summary
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- A summary of the key research
- Safety and side effects
- A link to the PubMed results
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
03Safety
Tirzepatide side effects and interactions
Side effects
Common
- Nausea (most common, 24-33% depending on dose, typically transient)
- Diarrhea (17-23%)
- Vomiting (6-13%, more common during titration)
- Decreased appetite (considered both effect and side effect)
- Constipation (6-11%)
- Injection site reactions (3-7%)
Serious events
- Pancreatitis (rare but reported — discontinue if suspected)
- Gallbladder disorders including cholelithiasis with rapid weight loss
- Medullary thyroid carcinoma (MTC) boxed warning based on rodent C-cell tumor findings
- Hypoglycemia when combined with insulin or sulfonylureas
- Acute kidney injury secondary to dehydration from GI side effects
Who should not use it
Contraindications
Personal or family history of MTC. MEN 2 syndrome. History of pancreatitis. Severe GI disease. Pregnancy or breastfeeding.
Interactions
5 pairings in our record: 2 to avoid, 2 with a caution and 1 noted as compatible or synergistic. Compatible and synergistic are notes from the record, not safety findings.
Semaglutide
AvoidBoth are GLP-1 agonists — do not combine
Retatrutide
AvoidRetatrutide includes GLP-1 agonism — redundant and dangerous
MK-677
CautionTirzepatide reduces appetite while MK-677 increases it — opposing effects
Tesofensine
CautionBoth suppress appetite strongly — risk of malnutrition
Cagrilintide
SynergisticGLP-1 + amylin combo (CagriSema) is being studied clinically
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
Need bloodwork before starting?
Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.
04Dosing
Free with emailTirzepatide dosage and protocols
- Dose range
- 2500 mcg (2.5 mg) starting dose, titrated every 4 weeks through 5000, 7500, 10000, 12500, to 15000 mcg (15 mg) maximum weekly dose
- Dosing
- Once weekly subcutaneous injection
- Common vials
- 5mg, 10mg, 15mg
Unlock the dosing protocols
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- Dose, route, how often and how long
- A titration schedule
- Beginner, intermediate and advanced protocols
- Reconstitution and handling notes
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
05Prices
Tirzepatide prices
14 listings from 4 vendors, opening in the Featured order.
- Pack prices
- $49.00 to $349.99
- Lowest per mg
- $2.48/mg
- Vendors
- 4
- Listings
- 14 (vial)
Prices as the vendors list them, last recorded 8 October 2026.
| Vendor | Product | Price | Buy |
|---|---|---|---|
RC-2T 60mg vial, 60mg vial In stock | $5.00/mg $299.99 | Buy RC-2T 60mg at ResearchChemHQ | |
Tirzepatide (ION-2T) 10mg vial, 1 vial In stock | $4.90/mg $49.00 | Buy Tirzepatide (ION-2T) 10mg at Ion Peptide | |
Tirzepatide (ION-2T) 20mg vial, 1 vial Out of stock | $4.25/mg $85.00 | View Tirzepatide (ION-2T) 20mg at Ion Peptide | |
Tirzepatide (ION-2T) 30mg vial, 1 vial Out of stock | $3.62/mg $108.50 | View Tirzepatide (ION-2T) 30mg at Ion Peptide | |
Tirzepatide (ION-2T) 40mg vial, 1 vial In stock | $3.23/mg $129.00 | Buy Tirzepatide (ION-2T) 40mg at Ion Peptide | |
Tirzepatide (ION-2T) 60mg vial, 1 vial In stock | $2.48/mg $149.00 Lowest per mg | Buy Tirzepatide (ION-2T) 60mg at Ion Peptide | |
Tirzepatide (ION-2T) 100mg vial, 1 vial Out of stock | $1.99/mg $199.00 | View Tirzepatide (ION-2T) 100mg at Ion Peptide | |
Tirzepatide 10mg vial, 1 vial In stock | $8.00/mg $79.99 | Buy Tirzepatide 10mg at BioMyst Labs | |
Tirzepatide 10mg vial, 1 vial In stock | $9.00/mg $89.99 | Buy Tirzepatide 10mg at BioMyst Labs | |
GLP-Tirz (Tirzepatide) 5mg vial, 5mg vial In stock | $12.00/mg $59.99 | Buy GLP-Tirz (Tirzepatide) 5mg at Half Nattys | |
GLP-Tirz (Tirzepatide) 10mg vial, 10mg vial In stock | $9.00/mg $89.99 | Buy GLP-Tirz (Tirzepatide) 10mg at Half Nattys | |
GLP-Tirz (Tirzepatide) 15mg vial, 15mg vial In stock | $7.33/mg $109.99 | Buy GLP-Tirz (Tirzepatide) 15mg at Half Nattys | |
GLP-Tirz (Tirzepatide) 30mg vial, 30mg vial In stock | $6.33/mg $189.99 | Buy GLP-Tirz (Tirzepatide) 30mg at Half Nattys | |
GLP-Tirz (Tirzepatide) 60mg vial, 60mg vial In stock | $5.83/mg $349.99 | Buy GLP-Tirz (Tirzepatide) 60mg at Half Nattys |
Vendors selling Tirzepatide(4: trust score, certificates, payment, shipping)
- Ion Peptide6 listings, from $49.00
Trust Score 70/100, no certificate records on file, pays by card, crypto, ACH, ships to the US, international destinations
- Half Nattys5 listings, from $59.99
Trust Score 50/100, 0 of 31 certificate records read, pays by card, crypto, Zelle, ships to the US
- BioMyst Labs2 listings, from $79.99
Trust Score 70/100, no certificate records on file, pays by card, crypto, ships to the US, international destinations
- ResearchChemHQ1 listing, from $299.99
Trust Score 100/100, 6 of 6 certificate records read, pays by card, crypto, ships to the US
Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors
Price history(3 days with a recorded price)
06Chemistry
Chemistry and structure
- Molecular formula
- C225H348N48O68
- Molecular mass
- 4813.49 g/mol
- CAS number
- 2023788-19-2
- IUPAC name
- Not fully specified (proprietary sequence)
- Amino acid sequence
- 39-amino-acid synthetic peptide agonist of both the GIP and GLP-1 receptors. Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser (one-letter: YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS, where X = Aib, 2-aminoisobutyric acid, at positions 2 and 13). Key modifications: the lysine at position 20 is conjugated through a gamma-glutamate + 2x AEEA [2-(2-aminoethoxy)ethoxy-acetyl] linker to a C20 fatty diacid (eicosanedioic acid), which drives albumin binding and the ~5-day half-life; the C-terminus is a primary amide. Molecular formula C225H348N48O68 (~4813.5 Da).
- Half-life
- ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification
08Questions
Frequently asked questions
How is tirzepatide dosed?
Tirzepatide is a once-weekly subcutaneous injection. The label starts everyone at 2.5 mg for the first four weeks (a tolerance dose, not a therapeutic one), then steps up to 5 mg, and can climb by 2.5 mg every four weeks up to a 15 mg maximum. Most people settle at the lowest dose that keeps working. There is a free tirzepatide dosage calculator on this site that converts any dose to syringe units.
Tirzepatide vs semaglutide: which is stronger?
Tirzepatide hits two receptors (GIP and GLP-1); semaglutide hits one (GLP-1). In the head-to-head trials, tirzepatide produced more weight loss and larger HbA1c drops. That does not make it right for everyone, but on raw efficacy it tends to win.
How long does a tirzepatide vial last?
Divide the vial size by your weekly dose. A 10 mg vial at 2.5 mg per week lasts about four weeks; at 5 mg per week, two. Reconstituted tirzepatide keeps roughly four to eight weeks refrigerated, so match the vial size to your dose.
How many vendors sell Tirzepatide, and what does it cost per mg?
4 of the vendors BodyHackGuide tracks list Tirzepatide (14 listings). Among BodyHackGuide's Tirzepatide listings recorded as in stock with a milligram count, the lowest price per milligram is $2.48/mg at Ion Peptide and the median is $6.33/mg. The Tirzepatide prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a Tirzepatide listing is dated 8 October 2026.
Which vendors have third-party COAs for Tirzepatide on file at BodyHackGuide?
BodyHackGuide holds 488 third-party certificate records for Tirzepatide, from Half Nattys. No editor has read any of BodyHackGuide's 488 certificate records for Tirzepatide. The laboratory named on BodyHackGuide's Tirzepatide certificate records is Freedom Diagnostics Testing, and the newest test date on them is 6 October 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.
Related
Articles on Tirzepatide
- The 8 Best Peptide Companies for Research: 2026 Purity & Price Comparisonvendor-reviews, 16 September 2026
- Myostatin: The Muscle Brake, the Inhibitors, and What Actually Works (2026)Guides, 9 July 2026
- Aquasome Nanotechnology and Oral Peptides: The Mechanism, the Research, and the 10 Compounds It Actually Works ForResearch, 20 May 2026
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.



